Emerging Novel Concept of Chaperone Therapies for Protein Misfolding Diseases

Overview

Journal Proc Jpn Acad Ser B Phys Biol Sci

Specialties Biology
Science

Date 2014 May 13

PMID 24814990

Citations 23

Authors

Yoshiyuki Suzuki

Affiliations

Soon will be listed here.

Abstract

Chaperone therapy is a newly developed molecular therapeutic approach to protein misfolding diseases. Among them we found unstable mutant enzyme proteins in a few lysosomal diseases, resulting in rapid intracellular degradation and loss of function. Active-site binding low molecular competitive inhibitors (chemical chaperones) paradoxically stabilized and enhanced the enzyme activity in somatic cells by correction of the misfolding of enzyme protein. They reached the brain through the blood-brain barrier after oral administration, and corrected pathophysiology of the disease. In addition to these inhibitory chaperones, non-competitive chaperones without inhibitory bioactivity are being developed. Furthermore molecular chaperone therapy utilizing the heat shock protein and other chaperone proteins induced by small molecules has been experimentally tried to handle abnormally accumulated proteins as a new approach particularly to neurodegenerative diseases. These three types of chaperones are promising candidates for various types of diseases, genetic or non-genetic, and neurological or non-neurological, in addition to lysosomal diseases.

Citing Articles

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.

Tenchov R, Sasso J, Zhou Q ACS Chem Neurosci. 2024; 15(15):2665-2694.

PMID: 38996083 PMC: 11311141. DOI: 10.1021/acschemneuro.4c00184.

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer.

Puhl A, Raman R, Havener T, Minerali E, Hickey A, Ekins S ACS Omega. 2024; 9(10):11870-11882.

PMID: 38496939 PMC: 10938339. DOI: 10.1021/acsomega.3c09607.

Promising Effect of High Dose Ambroxol Treatment on Neurocognition and Motor Development in a Patient With Neuropathic Gaucher Disease 2.

Aries C, Lohmoller B, Tiede S, Tauber K, Hartmann G, Rudolph C Front Neurol. 2022; 13:907317.

PMID: 35734474 PMC: 9207411. DOI: 10.3389/fneur.2022.907317.

Mucopolysaccharidosis III: Molecular basis and treatment.

Spahiu L, Behluli E, Peterlin B, Nefic H, Hadziselimovic R, Liehr T Pediatr Endocrinol Diabetes Metab. 2021; 27(3):201-208.

PMID: 34743503 PMC: 10228206. DOI: 10.5114/pedm.2021.109270.

GM1 Gangliosidosis-A Mini-Review.

Nicoli E, Annunziata I, dAzzo A, Platt F, Tifft C, Stepien K Front Genet. 2021; 12:734878.

PMID: 34539759 PMC: 8446533. DOI: 10.3389/fgene.2021.734878.

References

Desnick R, Schuchman E . Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012; 13:307-35. DOI: 10.1146/annurev-genom-090711-163739. View

Becq F, Mettey Y, Gray M, Galietta L, Dormer R, Merten M . Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem. 1999; 274(39):27415-25. DOI: 10.1074/jbc.274.39.27415. View

Wang G, Twigg G, Butters T, Zhang S, Zhang L, Zhang L . Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease. Org Biomol Chem. 2012; 10(15):2923-7. DOI: 10.1039/c2ob06987c. View

Noorwez S, Sama R, Kaushal S . Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal. J Biol Chem. 2009; 284(48):33333-42. PMC: 2785176. DOI: 10.1074/jbc.M109.043364. View

Nicoll A, Trevitt C, Tattum M, Risse E, Quarterman E, Ibarra A . Pharmacological chaperone for the structured domain of human prion protein. Proc Natl Acad Sci U S A. 2010; 107(41):17610-5. PMC: 2955083. DOI: 10.1073/pnas.1009062107. View

Nagai Y, Fujikake N, Popiel H, Wada K . Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol. 2010; 11(2):188-97. DOI: 10.2174/138920110790909650. View

Pedemonte N, Lukacs G, Du K, Caci E, Zegarra-Moran O, Galietta L . Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005; 115(9):2564-71. PMC: 1190372. DOI: 10.1172/JCI24898. View

Patnaik S, Zheng W, Choi J, Motabar O, Southall N, Westbroek W . Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem. 2012; 55(12):5734-48. PMC: 3400126. DOI: 10.1021/jm300063b. View

Nancarrow C, Wallace A, GREWAL A . The early pregnancy factor of sheep and cattle. J Reprod Fertil Suppl. 1981; 30:191-9. View

10.

Oshima A, Yoshida K, Shimmoto M, Fukuhara Y, Sakuraba H, Suzuki Y . Human beta-galactosidase gene mutations in morquio B disease. Am J Hum Genet. 1991; 49(5):1091-3. PMC: 1683264. View

11.

Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda A, Fu C, Sakamoto K . The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab. 2008; 94(3):283-6. PMC: 2587432. DOI: 10.1016/j.ymgme.2008.03.012. View

12.

Lee D, Santos D, Al-Rawi H, McNeill A, Rugg E . The chemical chaperone trimethylamine N-oxide ameliorates the effects of mutant keratins in cultured cells. Br J Dermatol. 2008; 159(1):252-5. DOI: 10.1111/j.1365-2133.2008.08596.x. View

13.

Fan J, Ishii S, Asano N, Suzuki Y . Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999; 5(1):112-5. DOI: 10.1038/4801. View

14.

Zhang R, Chen L, Jiralerspong S, Snowden A, Steinberg S, Braverman N . Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds. Proc Natl Acad Sci U S A. 2010; 107(12):5569-74. PMC: 2851769. DOI: 10.1073/pnas.0914960107. View

15.

Lampel A, Bram Y, Levy-Sakin M, Bacharach E, Gazit E . The effect of chemical chaperones on the assembly and stability of HIV-1 capsid protein. PLoS One. 2013; 8(4):e60867. PMC: 3618117. DOI: 10.1371/journal.pone.0060867. View

16.

Gonzales E, Grosse B, Cassio D, Davit-Spraul A, Fabre M, Jacquemin E . Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol. 2012; 57(3):695-8. DOI: 10.1016/j.jhep.2012.04.017. View

17.

Wellhauser L, Kim Chiaw P, Pasyk S, Li C, Ramjeesingh M, Bear C . A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol. 2009; 75(6):1430-8. DOI: 10.1124/mol.109.055608. View

18.

Bocharova N, Chave-Cox R, Sokolov S, Knorre D, Severin F . Protein aggregation and neurodegeneration: clues from a yeast model of Huntington's disease. Biochemistry (Mosc). 2009; 74(2):231-4. DOI: 10.1134/s0006297909020163. View

19.

Chaari A, Hoarau-Vechot J, Ladjimi M . Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease. Int J Biol Macromol. 2013; 60:196-205. DOI: 10.1016/j.ijbiomac.2013.05.032. View

20.

Conzelmann E, Sandhoff K . Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci. 1983; 6(1):58-71. DOI: 10.1159/000112332. View